From signal to asset.
At the speed of inference.
AlphaMeld unifies a 1.97-billion-edge biomedical knowledge graph, curated scientific agents, and live trial intelligence — so pharma teams compress target ID, validation, and TPP design from quarters into days.
An operating system for drug discovery — not a chatbot, not a database, not a dashboard.
We replace the patchwork of literature search, KG tools, trial trackers, and BD diligence with one orchestrated, evidence-linked system.
Reason over biology
A 1.97B-edge knowledge graph with chattel formalism for explainable, multi-hop traversal across targets, diseases, endpoints, drugs.
Knowledge Graph →Orchestrate agents
Curated scientific agents — safety, target ID, indication discovery, hypothesis validation — chain retrieval, tools, and verification.
Agent layer →De-risk decisions
Trial designer, phase-transition prediction, and TPP monitoring — your portfolio benchmarked against live competitor readouts.
AlphaCompass →Ship faster
Project-specific FastAPI workflows. KG → LLM verify → agentic deep-dive → diligence-grade deliverables. Reproducible at scale.
Workflows →Three surfaces, one substrate.
Every product reads from the same KG, the same evidence engine, the same agent orchestration layer. No data silos. No re-keying.
Discovery Navigator™
Guided scientific workflows, built on AlphaMeld's KG and chattel formalism. Target ID, indication discovery, hypothesis validation — diligence-grade reports out of the box.
Learn more →AlphaCompass®
Track every asset's Target Product Profile against real-world trial outcomes — yours and competitors'. Continuous monitoring, side-by-side benchmarking.
Learn more →ChatAlphaMeld™
Ask a question in plain English. Get a ranked, evidence-linked answer that traverses your KG, queries trials, and reasons through hypotheses.
Learn more →One query in. A program out.
The same agent orchestration runs across every workflow. Every step is auditable, every output reproducible.
The largest causally-grounded biomedical KG in production.
Updated continuously from PubMed, ClinicalTrials.gov, EMBL-EBI, NCBI, GTEx, Human Protein Atlas, and 30+ structured & unstructured sources. Your proprietary data layers on top — schema-mapped, never co-mingled.
Where AlphaMeld is in the field.
Modality-agnostic by design — small molecules, biologics, peptides, ADCs, and gene therapies all reason over the same biological substrate.
Multi-year pharma collaborations across rare, metabolic, and CNS indications.
AlphaMeld's knowledge graph and discovery agents have nominated targets, expanded indications, and accelerated pre-clinical programs across global pharma partnerships — including Kyowa Kirin, Shionogi, Ono Pharmaceutical, GSK Consumer Healthcare, Sosei Heptares, and TB Alliance.
AlphaMeld has produced multiple drug candidates that have entered clinical development, including the first AI-identified candidate to complete a successful Phase III trial.